In small, randomized, controlled trials, bisphosphonates (pamidronate, zoledronic acid) and selective estrogen-receptor modulators (raloxifene, toremifene) increased bone mineral density in GnRH ...
In another prospective study, 21 men with prostate cancer and bone metastases were randomly assigned, at study entry, to receive treatment with either pamidronate (90 mg) or placebo. [52] Patients ...